The Company ended the quarter with cash totaling $5.9M, compared to $3.7M as of December 31, 2024. During the Q3, the Company raised a total of approximately $1.7M of gross proceeds through purchases under the Equity Line of Credit. In addition, after quarter end, the Company raised an additional $1.4M from a warrant exercise by one institutional investor.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACXP:
- Acurx announces publication of results from ibezapolstat study
- Is ACXP a Buy, Before Earnings?
- Acurx Pharmaceuticals’ Ibezapolstat: Promising Preclinical and Clinical Efficacy Supports Buy Rating
- Acurx files to sell 585,000 shares of common stock for holders
- Acurx granted new patent for DNA Polymerase IIIC Inhibitors